Tyrosine kinase inhibitor (TKI) targeting epidermal growth factor receptor (EGFR) mutations significantly improves NSCLC prognosis in patients with EGFR mutations [10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.